RxDoctor Payments Data

George Pancio, MD

Cardiovascular Disease · Rochester, NYNPI 1427053743

Payments from drug & device makers

$1,518in general payments, 2019–2025

Across 79 payments — averaging $19.21 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novartis$468
  • Boehringer Ingelheim$125
  • Johnson & Johnson$118
  • Amgen$114
  • Pfizer$110
  • Merck$79
  • plus $505 from 17 others

What the payments were for

  • Food & beverage$1,518100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,518 in reported general payments places this provider in the 45th percentile of 2,302 cardiovascular disease providers in New York.

See all cardiovascular disease providers in New York

Medicare billing

Part B allowed, 2024
$51,288
Medicare patients
372
Services billed
1,158

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban408$484,020
XareltoRivaroxaban125$180,504
EntrestoSacubitril/Valsartan47$57,672
Repatha SureclickEvolocumab35$40,184
JardianceEmpagliflozin16$26,866
Praluent PenAlirocumab36$20,805
FarxigaDapagliflozin Propanediol12$18,151
Metoprolol Succinate573$11,176
Dofetilide29$10,805
Propafenone Hcl ErPropafenone Hcl43$8,781
Atorvastatin Calcium462$7,869
Rosuvastatin Calcium265$5,403
Amlodipine Besylate506$4,867
Ezetimibe58$4,155
Digoxin140$3,683

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$110$484,020408 claims
Johnson & JohnsonXarelto$118$180,504125 claims
NovartisEntresto$468$57,67247 claims
Boehringer IngelheimJardiance$125$26,86616 claims
AstraZenecaFarxiga$35$18,15112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 2,302 cardiovascular disease providers in New York.

Other cardiovascular disease in Rochester

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →